Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
23 October 2023 | Story Samkelo Fetile | Photo Supplied
The finalists in the 2023 Matriculant of the Year competition

In a culmination of academic prowess, leadership, sportsmanship, cultural achievements, and community engagement, the University of the Free State (UFS), Matriculant of the Year competition for 2023 has declared Michael de Bruyn, the head boy of Futurum Akademie in Tadcaster near Jan Kempdorp in the Northern Cape, as the 42nd winner. This prestigious event, in collaboration with Netwerk24 and Volksblad, witnessed the participation of 66 outstanding matriculants from eight provinces.

The journey to success for these matriculants was not only a test of academic acumen but a comprehensive evaluation of their leadership skills, involvement in sports and cultural activities, and commitment to community projects. The top 25 entrants were honoured with bursaries from the UFS, a testament to the institution's dedication to nurturing talent and fostering academic excellence.

The stakes were raised even higher for the top 14 finalists, who gathered at the Monte Bello Estate near Bloemfontein for the final judging. This phase involved personal interviews and group sessions, challenging the finalists to showcase not only their intellectual capabilities but also their interpersonal skills and collaborative spirit.

Sponsors and Supporters

Despite the economic challenges, the Matriculant of the Year competition has continued to thrive, thanks to the unwavering support of its sponsors. The final round judges, representing the Kovsie Alumni Trust, Absa, Mazars (official auditors), and Pick n Pay Preller Walk, played a crucial role in determining the ultimate winner.

In addition to the overall winner, the Kovsie Alumni Trust went above and beyond by sponsoring two special prizes for exceptional achievements in culture and sports. Ilke de Klerk of Goudveld-Hoërskool in Welkom received the sports accolade for her outstanding accomplishments in athletics and netball. Recognising cultural excellence, two accomplished pianists, Karli Janeke from St Dunstan’s College in Benoni and Elizabeth Joubert from C & N Meisieskool Oranje in Bloemfontein, were honoured for their exceptional contributions.

Culture and Sports Recognised

The spirit of the competition extends beyond academic and extracurricular achievements, acknowledging the vibrant personalities that contribute to a well-rounded community. Renienke van Heerden from Jim Fouché High School in Bloemfontein was voted as the sparkling personality, showcasing that the matriculants of 2023 are not only accomplished in their fields but also possess a captivating and engaging presence.

As the 42nd winner of the Matriculant of the Year competition, Michael de Bruyn stands as a beacon of inspiration for future generations and symbolises the UFS's commitment to recognising and nurturing excellence in all its forms. The competition serves not only as a celebration of academic achievement but also as a platform for the holistic development of young minds, moulding them into leaders, athletes, artists, and compassionate community members.

Nomonde Mbadi, Director at the Department of Student Recruitment Services, extends her congratulations to the finalists of the Matriculant of the Year 2023 competition. “I commend the learners for their outstanding achievements, and I do acknowledge the potential they carry for the future. May their accomplishments serve as inspiration for many others to pursue excellence and contribute positively to the world.”

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept